CDK inhibitors in hormone receptor positive advanced breast cancer

Abstract

Endocrine treatment is the current first line treatment in ER+advanced breast cancer with a requirement of predictivebiomarkers to the treatment and different approaches forendocrine resistance risk. Cyclin dependent kinases (CDKs)are regulating each step of cellular division in mammaliancell cycle and are hyperactivated in cancer cells causingcancer progression. Next generation pan-CDK inhibitors arein clinical development, while clinical trials in breast cancer,particularly in ER+ subtype where the greatest growthinhibition has been observed. Here I will review the datafrom this new class of drugs.Keywords: CDK inhibitors, Hormone positive advancedbreast cancer, Targeted therapies, Palbociclib, Endocrinetherapy resistance